Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical VT30 for Cutaneous Venous and Lymphatic Malformations
NCT04409145Phase 2Terminated
- Sponsor
- Venthera
- Start
- Oct 2020
- Primary completion
- Apr 2022
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VT30 in venous malformations (VM), Lymphatic Malformation (LM) and venolymphatic malformation (VLM), sponsored by Venthera. Primary endpoint: Evaluation of safety and tolerability at 4 weeks. Started Oct 2020; status: terminated.
02
Drugs
VT30
03
Conditions
venous malformations (VM)Lymphatic Malformation (LM)venolymphatic malformation (VLM)
Beyond the preview
Go deeper on NCT04409145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04409145.